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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1961Imaging to Detect Vulnerable PlaqueDavid Vancraeynest, Agnes Pasquet, Véronique Roelants, Bernhard L. Gerber, Jean-Louis J. Vanoverschelde
Arterial thrombosis is triggered by a ruptured atherosclerotic plaque that precipitates an acute
vascular event; rupture-prone plaques are called vulnerable plaques. In this review,
Vancraeynest and colleagues provide an overview of the invasive and noninvasive imaging
modalities that may be used to detect and characterize the vulnerability of plaques. The
techniques range from intravascular ultrasound, to computed tomography, and to targeted
nuclear tracer technologies. Each modality faces challenges prior to its adoption for clinical
practice.VIEWPOINT VIEWPOINT
1980Promoting Global Cardiovascular Health:
Access to Essential Cardiovascular MedicinesSandeep P. Kishore, Rajesh Vedanthan, Valentin Fuster
The United Nations will soon hold a high-level meeting on noncommunicable chronic
diseases (NCDs). Kishore and colleagues outline why this meeting provides the rare political
moment to generate commitments to scaling up national and international efforts to prevent
and treat NCDs, giving these illnesses the priority they deserve. This meeting is analogous to
a meeting 10 years earlier on human immunodeficiency virus (HIV)/autoimmune deficiency
syndrome (AIDS) that served as the nucleating event for a vigorous global and political
movement toward universal access to reliable, affordable, essential medicines to prevent and
treat HIV/AIDS. The authors use cardiovascular disease as a case study to examine the issue
of NCDs, outlining early solutions while drawing parallels and analogies to the HIV
experience.(continued on page A-25)
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iTRANSCATHETER AORTIC VALVE IMPLANTATION1988Prognostic Value of Myocardial Biomarkers After TAVIJosep Rodés-Cabau, Marcos Gutiérrez, Rodrigo Bagur, Robert De Larochellière, Daniel Doyle,
Mélanie Côté, Jacques Villeneuve, Olivier F. Bertrand, Eric Larose, Juan Manazzoni, Philippe Pibarot,
Eric Dumont
Rodés-Cabau and colleagues sought to determine the incidence, degree, and timing of cardiac
enzyme rise after transcatheter aortic valve implantation (TAVI) along with the prognostic
value of these measurements. TAVI was associated with some degree of myocardial injury in
99% of the patients as determined by a rise in cardiac troponin T (cTnT) (maximal value:
0.48 g/l) and in 77% of the patients as determined by a rise in creatine kinase-MB
maximal value: 18.6 g/l). Higher increases in both biomarkers were associated with a
maller improvement of left ventricular ejection fraction, and cTnT elevation was an
ndependent predictor of cardiac mortality during follow-up. These results provide important
nsights into the definition of myocardial infarction associated with TAVI procedures.CARDIAC GENETICS/GENOMICS
2000No Impact of KIF6 Genotype on Vascular Risk
or Statin Benefit in the Heart Protection StudyJemma C. Hopewell, Sarah Parish, Robert Clarke, Jane Armitage, Louise Bowman, Jorg Hager,
Mark Lathrop, Rory Collins, on behalf of the MRC/BHF Heart Protection Study Collaborative Group
Some evidence suggests that noncarriers of the KIF6 719Arg variant receive little benefit
from statin therapy. Hopewell and colleagues genotyped the almost 20,000 subjects from the
Heart Protection Study, which randomized subjects to simvastatin or placebo. Among
placebo-allocated participants, the KIF6 genotype was not significantly associated with the
risks of major vascular events, major coronary events, revascularizations, or strokes. Risk
reductions with simvastatin therapy were similar across KIF6 genotypes and endpoints. These
results suggest that KIF6 genotyping should not be used to guide statin therapy.(continued on page A-32)
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2008Timing of Valve Replacement in Patients With
Congenitally-Corrected Transposition of the Great ArteriesFrançois-Pierre Mongeon, Heidi M. Connolly, Joseph A. Dearani, Zhuo Li, Carole A. Warnes
Progressive systemic atrioventricular valve (SAVV) deterioration is common in patients with
congenitally-corrected transposition of the great arteries (CCTGA). Mongeon and colleagues
retrospectively reviewed 46 patients with CCTGA and SAVV regurgitation requiring surgery
to determine the relationship between pre-operative systemic ventricle ejection fraction
(SVEF) and long-term outcomes. The late SVEF was preserved (defined as 40%) in 63%
f patients operated with an SVEF 40% compared with only 11% of patients operated with
n SVEF 40%. These results suggest that SAVV replacement should be considered before
he SVEF falls below 40%.ditorial Comment: Emile Bacha, p. 2018PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCH
2020The Primary Benefits of ACE Inhibition on Cardiac Remodeling
Occur During Sleep-Time in Mouse ModelTami A. Martino, Nazneen Tata, Jeremy A. Simpson, Rachel Vanderlaan, Fayez Dawood,
M. Golam Kabir, Neelam Khaper, Carlo Cifelli, Peter Podobed, Peter P. Liu, Mansoor Husain,
Scott Heximer, Peter H. Backx, Michael J. Sole
Martino and colleagues investigated whether the effectiveness of angiotensin-converting
enzyme (ACE) inhibitors for cardiac remodeling exhibits a diurnal variation in a mouse
model. The short-acting ACE inhibitor captopril was given to mice that were subjected to
pressure overload by transverse aortic constriction (TAC) at either murine sleep time or wake
time for 8 weeks. TAC mice given captopril at sleep time had improved cardiac function and
significantly decreased heart/body weight ratios and myocyte cross-sectional areas compared
with TAC mice given captopril or placebo during wake time. These results support the
hypothesis that the heart (and vessels) remodels during sleep time and also illustrates the
importance of diurnal timing for some cardiovascular therapies.Editorial Comment: Bodh I. Jugdutt, p. 2029
